France-based EOS imaging has purchased the exclusive rights to scoliosis progression prognosis software technology.


The firm received the worldwide license for the technology that is devoted to the prognosis of adolescent scoliosis using 3D and 2D clinical parameters secured from EOS systems.

The algorithm of the acquired software, which has been developed by Montreal-based surgeons and engineers, uses several clinical parameters available in patient reports from the sterEOS workstation.

EOS imaging CEO Marie Meynadier said: "This promising technology confirms the value of the 3D data naturally associated with EOS images in developing applications and services dedicated to orthopedic care pathways.

"Acquiring these exclusive rights is an integral part of our global strategy to offer doctors not only cutting-edge imaging technology, but also a full suite of software and services to help them in their therapeutic strategies and execution, to the greatest benefit to patients."

To measure the technology’s ability to predict the risk of young patients with mild scoliosis, a multi-center clinical trial was launched in eight centres installed with EOS systems. These centres are located in the US, Canada, France, Japan, Singapore and Hong Kong.

It provides a predictive score, which could measure the risk of a patient at an early, mild stage of scoliosis developing a severe form of the pathology.

The firms plans to provide preliminary data on the predictive score at the 50th Scoliosis Research Society (SRS) meeting at Minneapolis, Minnesota, which will be held from 30 September to 3 October.

The EOS platform offers 2D and 3D full-body, stereo-radiographic images of patients in functional positions.

Image: EOS imaging has acquired the exclusive rights to scoliosis progression prognosis software technology. Photo: courtesy of Stuart Miles/